You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
AstraZeneca
McKesson
McKinsey
Medtronic

Last Updated: April 6, 2020

DrugPatentWatch Database Preview

Litigation Details for Elan Pharma International Limited v. Abraxis Bioscience Inc. (D. Del. 2006)


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Elan Pharma International Limited v. Abraxis Bioscience Inc. (D. Del. 2006)

Docket   Start Trial Date Filed 2006-07-19
Court District Court, D. Delaware Date Terminated 2011-03-02
Cause 28:1338 Patent Infringement Assigned To Gregory Moneta Sleet
Jury Demand Both Referred To
Parties ABRAXIS BIOSCIENCE INC.; ELAN PHARMA INTERNATIONAL LIMITED
Patents 10,066,017; 10,232,003; 5,145,684; 5,439,686; 5,498,421; 6,096,331; 6,506,405; 6,537,579; 6,749,868; 6,753,006; 7,101,576; 7,276,249; 9,228,018
Attorneys Diana B. Kruze; Elena C. Norman; Emily A. Evans; Eric S. Walters; Jeffrey D. Sullivan; Jeremy W. Bock; John G. Day; Josy W. Ingersoll; Karen Elizabeth Keller; Lauren E. Maguire; Michael A. Jacobs; Paul F. Coyne; Richard L. Horwitz; Steven J. Balick; Tiffany Geyer Lydon
Link to Docket External link to docket
Small Molecule Drugs cited in Elan Pharma International Limited v. Abraxis Bioscience Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .
Biologic Drugs cited in Elan Pharma International Limited v. Abraxis Bioscience Inc.

The biologic drugs covered by the patents cited in this case are   Start Trial ,   Start Trial , and   Start Trial .

Details for Elan Pharma International Limited v. Abraxis Bioscience Inc. (D. Del. 2006)

Date Filed Document No. Description Snippet Link To Document
2007-05-11 104 Claim Construction Opening Brief in U.S. Patent No. 5,145,684.”41 Like the ’363 Patent, the specification of the ’684 Patent states “useful…Unrted-States Patent 1191 nn Patent Number= 5,145,684 Liversidge et al. [45] Date of Patent: Sep. 8, 1992…Which issued as U.S. Patent No. 5,145,684 (“the ’684 Patent” ,28 the patentee indicated what “basic and… U.S. Patent Application Ser. No. 647,105 filed January 25, 1991, now U.S. Patent No. 5,145,684. Favorable…described in U.S. Patent Application Serial No. 908,125 and_parent U.S. Patent No. 5,145,684 provide a significant External link to document
2007-05-29 119 Notice (Other) means U.S. Patent No. 5,145,684. 5. The term “Foreign Counterpart” means any foreign patent application…“’363 Patent” means U.S. Patent No. 5,399,363. 2. The term “’025 Patent” means U.S. Patent No. 5,…term “Patents-In-Suit” means the ’363 Patent and the ’025 Patent. 4. The term “’684 Patent” means…term “Related Applications and Patents” means United States patents or patent applications that claim… Patents. 3. Documents constituting or referring to the Patents-In-Suit, the ’684 Patent, the External link to document
2007-06-01 125 Notice to Take Deposition means U.S. Patent No. 5,145,684. pa-1169027 Case 1:06-cv-00438-GMS Document 125 …“’363 Patent” means U.S. Patent No. 5,399,363. 4. The term “’025 Patent” means U.S. Patent No. 5,…term “Patents-In-Suit” means the ’363 Patent and the ’025 Patent. 6. The term “’684 Patent” means…term “Related Applications and Patents” means United States patents or patent applications that …specifically listed in the ’363 Patent, the ’025 Patent, or the ’684 Patent. pa-1169027 Case 1:06 External link to document
2007-06-22 141 Claim Construction Opening Brief in U.S. Patent No. 5,145,684.”41 Like the ’363 Patent, the specification of the ’684 Patent states “useful…which issued as U.S. Patent No. 5,145,684 (“the ’684 Patent”),28 the patentee indicated what “basic and…647,105, Jan. 25, 1991, Pat. No. 5,145,684). 29 Ex. 6 at A0044 (’684 Patent Prosecution History, Amendment…terms in the patents-in-suit, U.S. Patent No. 5,399,363 (“the ’363 Patent”) and U.S. Patent No. 5,834,025…f11e histories of the patents-in-suit and of the parent patent to the ’363 Patent. 1 Case 1:06-cv-00438 External link to document
2007-06-29 159 Redacted Document of U.S. patent application Ser. No. 647,105, filed Jan. 25 1991, now U.S. Patent No. 5,145,684, the disclosure…of the ‘363 Patent and the ‘025 Patent both relate to the nanoparticles of the ‘684 Patent, either by …‘025 Patent is similar to the same phrase recited in the ‘363 Patent. However, in the ‘025 Patent, the…..................... 6 A. U.S. Patent NO. 5,399,363 (“the ‘363 Patent”) .............................….................... 24 B. U.S. Patent No. 5,832,025 (“the ‘025 Patent”) ............................. External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Boehringer Ingelheim
AstraZeneca
Express Scripts
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.